STAT+: Why Gilead can’t stop talking about its ambitions in immunology
Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.